newsfilter
← Latest News
GlobeNewswire·

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

  • Cytek Biosciences Inc. (NASDAQ: CTKB) will showcase its advanced spectral flow cytometry solutions at the ESCCA 2026 Conference in Salzburg, Austria (September 9–12) & the ICCS 2026 Annual Meeting in Miami, Florida (October 2–6).
  • The company's Full Spectrum Profiling (FSP) technology enables analysis of complex panels & deeper insights across research & clinical applications, supported by over 4,200 peer-reviewed publications.
  • At ESCCA 2026, Cytek will exhibit at Booth PL2 & host an Industrial Partner Presentation on September 11 titled "Do We Really Need 40 Colors?" led by Dr. Mikael Roussel regarding spectral cytometry in routine diagnostics & minimal residual disease monitoring.
  • At ICCS 2026, Cytek will exhibit at Booths 100/101 & host a Corporate Workshop on October 4.
  • Cytek will host Key Opinion Leader (KOL) dinners at both events to facilitate discussions on the evolving role of spectral flow cytometry in clinical laboratories.
  • CEO Wenbin Jiang emphasized the company's goal to advance spectral flow cytometry adoption for improving efficiency, standardization, & analytical capabilities in MRD research & other translational applications.
  • Cytek's product portfolio includes the Aurora™, Northern Lights™, Aurora™ CS, Aurora™ Evo, Muse® Micro, Orion™, Amnis®, & Guava® systems, though most products are for research use only with limited clinical availability in China & the European Union.